Latest news
Patients in Illinois starting to receive experimental pancreatic cancer drug: ‘Game changer’ - Chicago TribuneChicago Tribune · Sun, 09 Aug 2026 11:00:17 GMTWhy Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next - simplywall.stsimplywall.st · Sat, 08 Aug 2026 19:45:53 GMT'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug - The Business JournalsThe Business Journals · Fri, 07 Aug 2026 13:29:00 GMTTango hopes it takes two: vopimetostat combos build on Revolution's pancreatic cancer breakthrough - FirstWord PHARMAFirstWord PHARMA · Thu, 06 Aug 2026 14:48:37 GMTFDA Accepts daraxonrasib Application for RAS-Mutant Pancreatic Cancer - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 06 Aug 2026 06:43:58 GMTRevolution Medicines Q2 Earnings Call Highlights - TradingViewTradingView · Thu, 06 Aug 2026 04:03:00 GMTRevolution Medicines preps for pancreatic drug launch, boosting expected 2026 expenses - Endpoints NewsEndpoints News · Thu, 06 Aug 2026 01:31:00 GMTRVMD: FDA accepted daraxonrasib NDA; net loss rose to $644M, cash reserves reached $3.9B - TradingViewTradingView · Wed, 05 Aug 2026 20:10:21 GMT